Skip to main content

Table 1 Baseline characteristics of HIV-1 infected women enrolled in the Kesho Bora study, by intervention arm (N = 1070)

From: Maternal anaemia and duration of zidovudine in antiretroviral regimens for preventing mother-to-child transmission: a randomized trial in three African countries

Characteristic n (%)

Cohort 1:

Cohort 2:

RCT arm A:

RCT arm B:

ART (CD4 < 200)

ZDV plus sdNVP (CD4 > 500)

Triple ARV (CD4 200–500)

ZDV plus sdNVP (CD4 200–500)

(n = 118)

(n = 128)

(n = 412)

(n = 412)

Country

    

 Burkina Faso

46 (39.0)

48 (38)

128 (31.1)

123 (29.9)

 Kenya

72 (61.0)

80 (62)

141 (34.2)

148 (35.9)

 South Africa

---

---

143 (34.7)

141 (34.2)

Age (years) median (IQR)

28 (26–31)

26 (23–29)

27 (24–31)

27 (23–31)

Highest level of education attained

    

 Never attended school

19 (16.1)

16 (12.5)

60 (14.6)

63 (15.3)

 Primary

57 (48.3)

61 (47.7)

136 (33.0)

147 (35.7)

 Secondary or higher

42 (35.6)

51 (39.8)

216 (52.4)

202 (49.0)

WHO HIV clinical stage

    

 1

28 (23.7)

100 (78.1)

279 (67.7)

296 (71.8)

 2

41 (34.8)

23 (18.0)

109 (26.5)

93 (22.6)

 3

25 (21.2)

5 (3.9)

24 (5.8)

23 (5.6)

 4

24 (20.3)

0 (0)

0 (0)

0 (0)

Nutritional status (BMI kg/m2)

    

 Mean (SD)

25 (3.8)

26 (4.1)

27 (4.3)

27 (4.3)

 Underweight: BMI < 18.5

3 (2.5)

1 (0.8)

1 (0.2)

2 (0.5)

Socio-economic quintile

    

 Most poor

30 (25.4)

32 (25.0)

66 (16.0)

81 (19.7)

 Very poor

29 (24.6)

36 (28.1)

83 (20.1)

71 (17.2)

 Poor

27 (22.9)

35 (27.3)

72 (17.5)

80 (19.4)

 Less poor

25 (21.2)

16 (12.5)

96 (23.3)

79 (19.2)

 Least poor

7 (5.9)

9 (7.0)

95 (23.1)

101 (24.5)

Parity

    

 Nulliparous (first pregnancy)

9 (7.6)

28 (21.9)

74 (18.0)

74 (18.0)

 1

34 (28.8)

44 (34.4)

131 (31.8)

145 (35.2)

 2

38 (32.2)

24 (18.7)

105 (25.5)

98 (23.8)

 3 or more

37 (31.4)

32 (25.0)

102 (24.8)

95 (23.1)

Planned mode of feeding

    

 Breastfeeding

60 (50.9)

92 (71.9)

300 (72.8)

297 (72.1)

 Replacement feeding

55 (46.6)

29 (22.6)

105 (25.5)

103 (25.0)

 Unknown, undecided or other

3 (2.5)

7 (5.5)

7 (1.7)

12 (2.9)

  1. ART = antiretroviral therapy; triple ARV = triple-combination antiretroviral prophylaxis; ZDV plus sdNVP = zidovudine plus single-dose nevirapine; IQR = interquartile range; std dev = standard deviation.